Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions Overall, olaparib improves PFS and reduces the risk of progression in HER2-negative BRCA-mutated MBC relative to physicians' choice chemotherapy. OlympiAD results hold limited internal and external validity, and follow-up may be insufficient to capture the risk of recurrence or second primary development. While patients are selected based on a confirmed deleterious gBRCAm, there is currently no established biomarker for response to PARPi. Clinical utility of olaparib may be limited as three mechanisms of resistance have already been established. Increasing use of platinum therapy in early TNBC may furthermore influence PARPi use, whilst the optimal PARPi-chemotherapy drug combination remains to be established. Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Humans; Phthalazines; Piperazines; olaparib Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32017000423 Date abstract record published 06/11/2017 |